In conversation with AFT Pharmaceuticals CEO, Dr Hartley Atkinson
As we exit the winter season, supporting our bodies' immunity to fight off those ills and chills is still essential. In doing so, knowing what brands to trust with your health and wellness products plays an important part. Remix chats with New Zealand-based Pharmaceutical company, AFT Pharmaceuticals CEO, Dr Hartley Atkinson - you may know them from their popular Lipo Sachets you can find at your local pharmacy - to talk about their latest advancements in the development and research of their groundbreaking products and what we can expect to see from them next.
Can you provide an overview of AFT Pharmaceuticals and its core areas of focus within the healthcare industry?
AFT Pharma is focussed around 7 therapeutic areas being, pain, eyecare, medicated vitamins, allergy, gastrointestinal, dermatology, hospital injectables. We also undertake our own drug development work within these categories and have products approved in over 60 countries around the globe.
Sales-wise, what are some of your highest performing products? Why do you think this is?
Our flagship product is Maxigesic which is sold in many countries including Austrailia & New Zealand. It is successful because it offers a viable alternative to opioids. However AFT is also successful in other areas - for example we have worked with a European based company on liposomal vitamins which result in improved absorption. With recent concerns from consumers around bolstering their immunity we have had excellent sales of Vitamin C Lipo-Sachets for example in New Zealand and also recently in Australia and even via our TMall site into China.
via Pinterest
How does AFT Pharmaceuticals approach research and development? What are the company's strategies for identifying and developing new drugs or treatments?
We are looking for diseases that likely the standard global big pharma would not be involved in but are areas where patients still have a significant need. One such example is we are developing a drug for topical treatment of strawberry birthmarks which can disfigure newborns. Another is a treatment for eye infections caused by drug resistant superbugs which is pretty important as a patient could otherwise go blind.
Can you talk about any recent advancements or milestones achieved by AFT Pharmaceuticals in the field of pharmaceuticals?
We were pleased to obtain regulatory approval for our patented Maxigesic Rapid in the USA after approval by FDA. This is a first for a local New Zealand company - approval of a patented drug with clinical trial data.
via Pinterest
Looking into the future, what are your goals and visions for AFT Pharmaceuticals? Are there any upcoming projects or plans that you can share with us?
We are looking to secure our 2nd US FDA approval later this year for Maxigesic IV (the intravenous form of Maxigesic used in hospitals) which will be a major milestone for our company. Following that we are working to launch and commercialize these 2 products in USA which is world’s largest pharma market.
Advertisement
